A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

This study is being done to learn more about Lipoprotein(a) values in people with known history of Atherosclerotic Cardiovascular Disease (ASCVD). The study is being done to identify the people with history of myocardial infarction (MI) and/or percutaneous coronary intervention (PCI) that have an Lp(a) level of at least 90 mg/dL or 200 nmol/L. Lipoprotein(a) is a particle that carries cholesterol in the blood and is a known risk factor for cardiovascular disease (CVD). High levels of Lp(a) are directly associated with a higher risk of cardiovascular events such as heart attacks or aortic stenosis. Unlike other lipid risk factors, for example blood cholesterol levels, that can be influenced by diet, exercise, or obesity, Lp(a) levels are inherited and stay stable from childhood. Until more recently, the role of Lp(a) was not well understood and therefore it was not routinely tested for. This study aims to collect data on Lp(a) in ASCVD patients to understand better the distribution of this risk in such patients. Subjects enrolled into this study maybe invited to participate in future Amgen-sponsored LP(a) lowering clinical trials. The purpose of this study is to characterize the distribution of Lp(a) levels among subjects with a history of ASCVD as defined by their medical history and is 2-fold: 1)Evaluate the distribution of Lp(a) value in the overall subjects with documented history of myocardial infarction(MI) and/or percutaneous coronary intervention(PCI) 2)Evaluate the distribution of Lp(a) valuve in subjects with documented history of MI and/or PCI by demographics and regions.